Breast CancerNCT00874211
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
An observational study of Breast Cancer and Lung Cancer, run by SWOG Cancer Research Network at 453 sites in 3 countries.
Trial summary
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care. Read more about this study
- Who is it for?
- Ages Up to 120 years
- Conditions the study is for
- Breast Cancer, Lung Cancer, Metastatic Cancer
- What is being tested?
- assessment of therapy complications
- Type of treatment
- Surgery or procedure
- How many people
- 3,571 participants
- Where
- 453 sitesin 3 countries
- Study dates
- Dec 2008to Jun 2019
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Up to 120 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: SWOG membership and CCOP participants through CTSU.
DISEASE CHARACTERISTICS:
- Participant must have bone metastasis from multiple myeloma, solid tumors, or other malignancy for which intravenous bisphosphonate has clinical indications in the treatment of metastatic bone disease
- Treatment with osteoclast inhibition is clinically indicated
- Must be planning to receive zoledronic acid* within the next 30 days NOTE: *Osteoclast inhibition therapy will continue thereafter as clinically indicated.
- No prior diagnosis of osteonecrosis of the jaw
- Patients previously treated with osteoclast inhibition therapy are eligible, provided the following criteria apply:
- Prior osteoclast inhibition for low bone mass (osteoporosis or osteopenia):
- Patients may have previously received at most 3 doses of osteoclast-inhibiting therapy with denosumab, IV ibandronate, pamidronate, or zoledronic acid for low bone mass (osteopenia or osteoporosis) within 3 years prior to registration
- Prior oral bisphosphonate therapy at osteoporosis or osteopenia dosing at any time prior to registration is allowed
- Prior exposures to other medications used to treat low bone mass at osteoporosis or osteopenia dosing are permitted
- Prior osteoclast inhibition for metastatic bone disease (tumor involving bone):
- Patients may have previously received osteoclast-inhibiting therapy with denosumab, ibandronate (oral or IV cancer dosing), pamidronate, or zoledronic acid to treat metastatic bone disease within 180 days prior to registration
- Patients receiving these regimens for metastatic bone disease prior to 180 days before registration are not eligible
- Prior osteoclast-inhibiting therapy at higher dosing than outlined above at any time prior to registration is not allowed
PATIENT CHARACTERISTICS:
- Zubrod performance status 0-3
- Patients who may be acutely ill from spinal cord compromise, hypercalcemia of malignancy, or other process may be study candidates once the acute condition has been addressed and performance status improves to 0-3
- Not pregnant or nursing
- Negative pregnancy test
- Willing and physically able to comply with study procedures and assessments
- Willing to provide information on personal history, including tobacco and alcohol use, and pain assessment
- Willing to provide access to prior and future dental information
- No other prior malignancy except for any of the following:
- Adequately treated basal cell carcinoma or squamous cell carcinoma of the skin
- In situ cervical cancer
- Adequately treated stage I or II cancer for which the patient is currently in complete remission
- Any other cancer for which the patient has been disease-free for 5 years
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
- No history of radiation to the maxillofacial area administered for therapeutic intent in the treatment of cancer
- Concurrent participation in other therapeutic and non-therapeutic clinical trials allowed
- The sum of prior IV bisphosphonate doses must not be greater than 10
- The sum of prior denosumab doses must not be greater than 8
- The total of both IV bisphosphonate and denosumab used for any indication must not be greater than 12 doses
Trial locations and contacts
453 sites in 3 countries.
302 sites in 3 countries
United States300 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Hematology Oncology Associates, PC
Albuquerque, New Mexico, 87106
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Harrington Cancer Center
Amarillo, Texas, 79106
American Fork Hospital
American Fork, Utah, 84003
McFarland Clinic, PC
Ames, Iowa, 50010
Island Hospital Cancer Care Center at Island Hospital
Anacortes, Washington, 98221
Providence Cancer Center
Anchorage, Alaska, 99508
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, 48109-0942
Regional Medical Center
Anniston, Alabama, 36207
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Piedmont Hospital
Atlanta, Georgia, 30309
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
Rush-Copley Cancer Care Center
Aurora, Illinois, 60504
WellStar Cobb Hospital
Austell, Georgia, 30106
Ochsner Health Center - Bluebonnet
Baton Rouge, Louisiana, 70809
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
Bay Regional Medical Center
Bay City, Michigan, 48708
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
St. Joseph Cancer Center
Bellingham, Washington, 98225
Study site
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59102
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, 83712
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
St. Joseph's Medical Center
Brainerd, Minnesota, 56401
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Highline Medical Center Cancer Center
Burien, Washington, 98166
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Southeast Cancer Center
Cape Girardeau, Missouri, 63703
Memorial Hospital of Carbondale
Carbondale, Illinois, 62902
Rocky Mountain Oncology
Casper, Wyoming, 82609
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California, 94546
Sandra L. Maxwell Cancer Center
Cedar City, Utah, 84720
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
John H. Stroger, Jr. Hospital of Cook County
Chicago, Illinois, 60612-3785
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Charles M. Barrett Cancer Center at University Hospital
Cincinnati, Ohio, 45267
Clackamas Radiation Oncology Center
Clackamas, Oregon, 97015
Medical Oncology and Hematology Associates - West Des Moines
Clive, Iowa, 50325
Memorial Hospital Cancer Center - Colorado Springs
Colorado Springs, Colorado, 80909
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
John B. Amos Cancer Center
Columbus, Georgia, 31904
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Cancer Care Center at John Muir Health - Concord Campus
Concord, California, 94524-4110
Cookeville Regional Medical Center
Cookeville, Tennessee, 38501
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Ochsner Health Center - Covington
Covington, Louisiana, 70433
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
Grady Memorial Hospital
Delaware, Ohio, 43015
St. Anthony Central Hospital
Denver, Colorado, 80204
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80222
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at John Stoddard Cancer Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
Cancer Centers of the Carolinas - Easley
Easley, South Carolina, 29640
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Fairview Southdale Hospital
Edina, Minnesota, 55435
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Sherman Hospital
Elgin, Illinois, 60123
Elkhart Clinic, LLC
Elkhart, Indiana, 46514-2098
Michiana Hematology-Oncology, PC - Elkhart
Elkhart, Indiana, 46514
Elkhart General Hospital
Elkhart, Indiana, 46515
Union Hospital of Cecil County
Elkton, Maryland, 21921
Falck Cancer Center at Arnot Ogden Medical Center
Elmira, New York, 14905
Community Cancer Center
Elyria, Ohio, 44035
Hematology Oncology Center
Elyria, Ohio, 44035
Swedish Medical Center
Englewood, Colorado, 80110
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Evanston Hospital
Evanston, Illinois, 60201-1781
Providence Regional Cancer Partnership
Everett, Washington, 98201
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
North Bay Cancer Center
Fairfield, California, 94533
Piedmont Fayette Hospital
Fayetteville, Georgia, 30214
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
McLaren Cancer Institute
Flint, Michigan, 48532
Singh and Arora Hematology Oncology, PC
Flint, Michigan, 48532
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Broward General Medical Center Cancer Center
Fort Lauderdale, Florida, 33316
Brooke Army Medical Center
Fort Sam Houston, Texas, 78234-6200
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
Valley Medical Oncology
Fremont, California, 94538
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Saint Luke's Mountain States Tumor Institute - Fruitland
Fruitland, Idaho, 83619
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
University of Texas Medical Branch
Galveston, Texas, 77555-0361
Delnor Hospital - Geneva
Geneva, Illinois, 60134
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Three Rivers Community Hospital
Grants Pass, Oregon, 97527
Sierra Nevada Cancer Center at Sierra Nevada Memorial Hospital
Grass Valley, California, 95945
Big Sky Oncology
Great Falls, Montana, 59405-5309
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Wayne Hospital
Greenville, Ohio, 45331
Bon Secours St. Francis Health System
Greenville, South Carolina, 29601
Cancer Centers of the Carolinas - Faris Road
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Grove Commons
Greenville, South Carolina, 29605
Greenville Hospital Cancer Center
Greenville, South Carolina, 29605
Cancer Centers of the Carolinas - Eastside
Greenville, South Carolina, 29615
CCOP - Greenville
Greenville, South Carolina, 29615
Self Regional Cancer Center at Self Regional Medical Center
Greenwood, South Carolina, 29646
Cancer Centers of the Carolinas - Greer Medical Oncology
Greer, South Carolina, 29650
Cancer Centers of the Carolinas - Greer Radiation Oncology
Greer, South Carolina, 29650
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
St. Peter's Hospital
Helena, Montana, 59601
Pardee Memorial Hospital
Hendersonville, North Carolina, 28791
Veterans Affairs Medical Center - Hines
Hines, Illinois, 60141
Cancer Research Center of Hawaii
Honolulu, Hawaii, 96813
OnCare Hawaii, Incorporated - Lusitana
Honolulu, Hawaii, 96813
Queen's Cancer Institute at Queen's Medical Center
Honolulu, Hawaii, 96813
Straub Clinic and Hospital, Incorporated
Honolulu, Hawaii, 96813
Hawaii Medical Center - East
Honolulu, Hawaii, 96817
OnCare Hawaii, Incorporated - Kuakini
Honolulu, Hawaii, 96817
Kapiolani Medical Center for Women and Children
Honolulu, Hawaii, 96826
Tripler Army Medical Center
Honolulu, Hawaii, 96859
M. D. Anderson Cancer Center at University of Texas
Houston, Texas, 77030-4009
Baylor University Medical Center - Houston
Houston, Texas, 77030
Ben Taub General Hospital
Houston, Texas, 77030
St. Luke's Texas Cancer Institute at St. Luke's Episcopal Hospital
Houston, Texas, 77030
Veterans Affairs Medical Center - Houston
Houston, Texas, 77030
Hutchinson Area Health Care
Hutchinson, Minnesota, 55350
Cancer Center of Kansas-Independence
Independence, Kansas, 67301
Dickinson County Healthcare System
Iron Mountain, Michigan, 49801
Swedish Medical Center - Issaquah Campus
Issaquah, Washington, 98029
Foote Memorial Hospital
Jackson, Michigan, 49201
University of Mississippi Cancer Clinic
Jackson, Mississippi, 39216
Veterans Affairs Medical Center - Jackson
Jackson, Mississippi, 39216
Goldschmidt Cancer Center
Jefferson City, Missouri, 65109
NEA Medical Clinic - East Matthews
Jonesboro, Arkansas, 72401
Borgess Medical Center
Kalamazoo, Michigan, 49001
West Michigan Cancer Center
Kalamazoo, Michigan, 49007-3731
Bronson Methodist Hospital
Kalamazoo, Michigan, 49007
Kalispell Medical Oncology at KRMC
Kalispell, Montana, 59901
Kalispell Regional Medical Center
Kalispell, Montana, 59901
Saint Luke's Cancer Institute at Saint Luke's Hospital
Kansas City, Missouri, 64111
North Kansas City Hospital
Kansas City, Missouri, 64116
Heartland Hematology Oncology Associates, Incorporated
Kansas City, Missouri, 64118
Veterans Affairs Medical Center - Kansas City
Kansas City, Missouri, 64128
Research Medical Center
Kansas City, Missouri, 64132
Good Samaritan Cancer Center at Good Samaritan Hospital
Kearney, Nebraska, 68848-1990
Columbia Basin Hematology
Kennewick, Washington, 99336
Charles F. Kettering Memorial Hospital
Kettering, Ohio, 45429
Cancer Center of Kansas, PA - Kingman
Kingman, Kansas, 67068
Cascade Cancer Center at Evergreen Hospital Medical Center
Kirkland, Washington, 98033
Howard Community Hospital
Kokomo, Indiana, 46904
Gundersen Lutheran Center for Cancer and Blood
La Crosse, Wisconsin, 54601
Center for Cancer Therapy at LaPorte Hospital and Health Services
La Porte, Indiana, 46350
Fairfield Medical Center
Lancaster, Ohio, 43130
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, 48910
Sparrow Regional Cancer Center
Lansing, Michigan, 48912-1811
Great Lakes Cancer Institute - Lapeer Campus
Lapeer, Michigan, 48446
University Medical Center of Southern Nevada
Las Vegas, Nevada, 89102
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, 89106
Nevada Cancer Institute
Las Vegas, Nevada, 89135
Lawrence Memorial Hospital
Lawrence, Kansas, 66044
Gwinnett Medical Center
Lawrenceville, Georgia, 30045
Saint Luke's East - Lee's Summit
Lee's Summit, Missouri, 64086
Tunnell Cancer Center at Beebe Medical Center
Lewes, Delaware, 19958
St. Joseph Regional Medical Center
Lewiston, Idaho, 83501
Cancer Center of Kansas, PA - Liberal
Liberal, Kansas, 67901
Parvin Radiation Oncology
Liberty, Missouri, 64068
Kauai Medical Clinic
Lihue, Hawaii, 96766
Lima Memorial Hospital
Lima, Ohio, 45804
Cancer Resource Center - Lincoln
Lincoln, Nebraska, 68510
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, 72205
Littleton Adventist Hospital
Littleton, Colorado, 80122
St. Mary Mercy Hospital
Livonia, Michigan, 48154
Logan Regional Hospital
Logan, Utah, 84321
Sky Ridge Medical Center
Lone Tree, Colorado, 80124
Breastlink Medical Group, Incorporated at Long Beach Memorial Medical Center
Long Beach, California, 90806
Hope Cancer Care Center at Longmont United Hospital
Longmont, Colorado, 80501
USC/Norris Comprehensive Cancer Center and Hospital
Los Angeles, California, 90089-9181
McKee Medical Center
Loveland, Colorado, 80539
Holy Family Memorial Medical Center Cancer Care Center
Manitowoc, Wisconsin, 54221-1450
HealthEast Cancer Care at St. John's Hospital
Maplewood, Minnesota, 55109
Minnesota Oncology - Maplewood
Maplewood, Minnesota, 55109
Kennestone Cancer Center at Wellstar Kennestone Hospital
Marietta, Georgia, 30060
Strecker Cancer Center at Marietta Memorial Hospital
Marietta, Ohio, 45750
Contra Costa Regional Medical Center
Martinez, California, 94553-3156
Tibotec Therapeutics - Division of Ortho Biotech Products, LP
Marysville, California, 95901
Mercy Cancer Center at Mercy Medical Center - North Iowa
Mason City, Iowa, 50401
Northwest Ohio Oncology Center
Maumee, Ohio, 43537-1839
Cardinal Bernardin Cancer Center at Loyola University Medical Center
Maywood, Illinois, 60153
Cancer Center of Kansas, PA - McPherson
McPherson, Kansas, 67460
Dubs Cancer Center at Rogue Valley Medical Center
Medford, Oregon, 97504
Providence Cancer Center at PMCC
Medford, Oregon, 97504
Mercy Cancer Center at Mercy Medical Center
Merced, California, 95340
Mountain States Tumor Institute - Meridian
Meridian, Idaho, 83642
Caritas Holy Family Hospital
Methuen, Massachusetts, 01844
Saint Anthony Memorial Health Centers
Michigan City, Indiana, 46360
Providence Milwaukie Hospital
Milwaukie, Oregon, 97222
Virginia Piper Cancer Institute at Abbott - Northwestern Hospital
Minneapolis, Minnesota, 55407
Hennepin County Medical Center - Minneapolis
Minneapolis, Minnesota, 55415
Michiana Hematology-Oncology, PC - South Bend
Mishawaka, Indiana, 46545-1470
Saint Joseph Regional Medical Center
Mishawaka, Indiana, 46545-1470
Montana Cancer Specialists at Montana Cancer Center
Missoula, Montana, 59807-7877
Montana Cancer Center at St. Patrick Hospital and Health Sciences Center
Missoula, Montana, 59807
Providence Cancer Center at Providence Hospital
Mobile, Alabama, 36608
Trinity Cancer Center at Trinity Medical Center - 7th Street Campus
Moline, Illinois, 61265
Study site
Moline, Illinois, 61265
Louisiana State University Health Sciences Center - Monroe
Monroe, Louisiana, 71210
Community Cancer Center of Monroe
Monroe, Michigan, 48162
Mercy Memorial Hospital - Monroe
Monroe, Michigan, 48162
Clemens Regional Medical Center
Mount Clemens, Michigan, 48043
Good Samaritan Regional Health Center
Mount Vernon, Illinois, 62864
Knox Community Hospital
Mount Vernon, Ohio, 43050
Skagit Valley Hospital Cancer Care Center
Mount Vernon, Washington, 98274
El Camino Hospital Cancer Center
Mountain View, California, 94040
Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
Murray, Utah, 84157
Mercy General Health Partners
Muskegon, Michigan, 49444
Saint Luke's Mountain States Tumor Institute
Nampa, Idaho, 83686
CCOP - Ochsner
New Orleans, Louisiana, 70121
Ochsner Cancer Institute at Ochsner Clinic Foundation
New Orleans, Louisiana, 70121
New Ulm Medical Center
New Ulm, Minnesota, 56073
CCOP - Christiana Care Health Services
Newark, Delaware, 19713
UMDNJ University Hospital
Newark, New Jersey, 07103
Licking Memorial Cancer Care Program at Licking Memorial Hospital
Newark, Ohio, 43055
Providence Newberg Medical Center
Newberg, Oregon, 97132
Cancer Center of Kansas, PA - Newton
Newton, Kansas, 67114
Highland General Hospital
Oakland, California, 94602
Alta Bates Summit Medical Center - Summit Campus
Oakland, California, 94609
Bay Area Breast Surgeons, Incorporated
Oakland, California, 94609
CCOP - Bay Area Tumor Institute
Oakland, California, 94609
Larry G Strieff MD Medical Corporation
Oakland, California, 94609
Tom K Lee, Incorporated
Oakland, California, 94609
Epic Care - Oakland
Oakland, California, 94612
Green Bay Oncology, Limited - Oconto Falls
Oconto Falls, Wisconsin, 54154
Val and Ann Browning Cancer Center at McKay-Dee Hospital Center
Ogden, Utah, 84403
Providence St. Peter Hospital Regional Cancer Center
Olympia, Washington, 98506-5166
CCOP - Missouri Valley Cancer Consortium
Omaha, Nebraska, 68106
Immanuel Medical Center
Omaha, Nebraska, 68122
Alegant Health Cancer Center at Bergan Mercy Medical Center
Omaha, Nebraska, 68124
Lakeside Hospital
Omaha, Nebraska, 68130
Creighton University Medical Center
Omaha, Nebraska, 68131-2197
Saudi Arabia1 site
King Faisal Specialist Hospital and Research Center
Riyadh, 11211
About this study
Official title: S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.
Read the detailed description
OBJECTIVES:
Primary
- To prospectively access the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.
Secondary
- To describe the clinical presentation and natural history of ONJ.
- To identify potential risk factors for the development of ONJ.
- To estimate the cumulative incidence of ONJ at 3 years for different tumor types (i.e., breast cancer, multiple myeloma, prostate cancer, lung cancer, and other cancers).
- To better define the patient-related outcomes of ONJ.
OUTLINE: This is a multicenter study.
Patients undergo dental assessments at baseline and every 3-6 months for 3 years.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer
- Being tested
- assessment of therapy complications
- Keywords
- bone metastases, unspecified adult solid tumor, protocol specific, refractory multiple myeloma, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, male breast cancer, recurrent breast cancer, stage IA breast cancer, stage IB breast cancer, stage II breast cancer, stage IIIA breast cancer, stage IIIB breast cancer, stage IIIC breast cancer, stage IV breast cancer, recurrent prostate cancer, stage I prostate cancer, stage IIB prostate cancer, stage IIA prostate cancer, stage III prostate cancer
- Medical subject headings
- Breast Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Multiple Myeloma, Neoplasms, Plasma Cell, Prostatic Neoplasms, Breast Neoplasms, Male, Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
assessment of therapy complicationsProcedure or surgery
By dental and medical assessments.
| Study group | Role | What they receive |
|---|---|---|
| Observation | Patients will be observed and will undergo assessment of therapy complications. Receives: Procedure: assessment of therapy complications |
What is being measured
The primary outcome is the main question the study is designed to answer.
Diagnosis of confirmed osteonecrosis of the jaw (ONJ)
Measured: 3 years
Secondary outcomes (5)
Disease-specific estimates of the confirmed cumulative incidence at 3 years of ONJ
Measured: 3 years
Clinical presentation and natural history of ONJ
Measured: 3 years
Overall and disease-specific cumulative incidence
Measured: 3 years
Association of baseline factors with cumulative incidence of confirmed ONJ
Measured: 3 years
Association between patient-related outcomes and confirmed incidence
Measured: 3 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Apr 2009 (estimated)
- Study startDec 2008
- Primary completionJun 2019
- Study completionJun 2019
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- More trials run by SWOG Cancer Research NetworkThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 3,571 participants (actual)
Sponsor and investigators
- Lead sponsor
- SWOG Cancer Research Network
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Novartis
- Responsible party
- Sponsor
- Investigators
- Catherine Van Poznak, MD, Study chair, University of Michigan Rogel Cancer CenterJulie R. Gralow, MD, Study chair, Seattle Cancer Care Alliance
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00874211
- Sponsor's protocol ID
- S0702
- Other IDs
- S0702, U10CA037429
- Status last verified
- Jul 2019
- First submitted
- 1 Apr 2009
- Last updated
- 5 Jul 2019
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Van Poznak CH, Darke A, Moinpour CM, Bagramian RA, Schubert MM, Gralow JR, Wade JL 3rd, Unger JM. Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. Support Care Cancer. 2017 Apr;25(4):1191-1199. doi: 10.1007/s00520-016-3509-3. Epub 2016 Dec 7.
PubMed 27928641
Study at a glance
From the registry record, last updated by the sponsor on 5 Jul 2019. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- S0702: A Prospective Observational Multicenter Cohort Study to Assess the Incidence of Osteonecrosis of the Jaw (ONJ) in Cancer Patients With Bone Metastases Starting Zoledronic Acid Treatment
- ClinicalTrials.gov ID
- NCT00874211
- Acronym / sponsor ID
- S0702
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma, Plasma Cell Neoplasm, Prostate Cancer
- Keywords
- bone metastases, unspecified adult solid tumor, protocol specific, refractory multiple myeloma, stage I multiple myeloma, stage II multiple myeloma, stage III multiple myeloma, male breast cancer, recurrent breast cancer
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 3,571 participants (actual)
- Lead sponsor
- SWOG Cancer Research NetworkResearch network
- Collaborators
- National Cancer Institute (NCI), Novartis
- Study start
- Dec 2008 (actual)
- Primary completion
- Jun 2019 (actual)
- Study completion
- Jun 2019 (actual)
- First posted
- 2 Apr 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.
Detailed description
OBJECTIVES:
Primary
- To prospectively access the cumulative incidence of osteonecrosis of the jaw (ONJ) at 3 years in cancer patients with bone metastasis receiving zoledronic acid treatment.
Secondary
- To describe the clinical presentation and natural history of ONJ.
- To identify potential risk factors for the development of ONJ.
- To estimate the cumulative incidence of ONJ at 3 years for different tumor types (i.e., breast cancer, multiple myeloma, prostate cancer, lung cancer, and other cancers).
- To better define the patient-related outcomes of ONJ.
OUTLINE: This is a multicenter study.
Patients undergo dental assessments at baseline and every 3-6 months for 3 years.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Observation | – | Procedure: assessment of therapy complicationsPatients will be observed and will undergo assessment of therapy complications. |
Who may qualify
- Ages
- Up to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- SWOG membership and CCOP participants through CTSU.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| assessment of therapy complicationsBy dental and medical assessments. | Procedure or surgery | Observation |
Primary outcome
Diagnosis of confirmed osteonecrosis of the jaw (ONJ)
Time frame: 3 years
5 secondary outcomes
Disease-specific estimates of the confirmed cumulative incidence at 3 years of ONJ
Time frame: 3 years
Clinical presentation and natural history of ONJ
Time frame: 3 years
Overall and disease-specific cumulative incidence
Time frame: 3 years
Association of baseline factors with cumulative incidence of confirmed ONJ
Time frame: 3 years
Association between patient-related outcomes and confirmed incidence
Time frame: 3 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Jul 2019.
- Derived from this study: PubMed 27928641Van Poznak CH, Darke A, Moinpour CM, Bagramian RA, Schubert MM, Gralow JR, Wade JL 3rd, Unger JM. Dental health status and patient-reported outcomes at baseline in patients participating in the osteonecrosis of the jaw registry study, SWOG S0702. Support Care Cancer. 2017 Apr;25(4):1191-1199. doi: 10.1007/s00520-016-3509-3. Epub 2016 Dec 7.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Catherine Van Poznak, MD study chair
University of Michigan Rogel Cancer Center
Julie R. Gralow, MD study chair
Seattle Cancer Care Alliance
453 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Breast Cancer and Lung Cancer, run by SWOG Cancer Research Network at 453 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Jul 2019. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 453 sites in United States, Mexico, Saudi Arabia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Diagnosis of confirmed osteonecrosis of the jaw (ONJ) (time frame: 3 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00874211, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Jul 2019.